TaiRx Enters China, Combining Novel Drug with Immunotherapy for Clinical Trials
TaiRx announced a Phase 2A clinical trial combining its novel cancer drug CVM-1118 with Innovent's antibody Sintilimab for liver cancer in China. This partnership saves 90% of trial costs. TaiRx also plans to raise NT$400-500 million and apply for an IPO this year.
📋 Article Processing Timeline
- 📰 Published: April 23, 2026 at 16:31
- 🔍 Collected: April 23, 2026 at 17:02 (30 min after Published)
- 🤖 AI Analyzed: April 23, 2026 at 17:45 (43 min after Collected)
Central News Agency
(CNA Reporter He Hsiu-ling, Taipei, 23rd) Lin Chun, Chairman of the novel drug company TaiRx, stated that their investigational anti-cancer drug CVM-1118 will be combined with the Chinese pharmaceutical company Innovent's antibody drug 'Sintilimab' to conduct a Phase 2A combination clinical trial for the treatment of liver cancer, and they will begin recruiting patients. Upon receiving regulatory approval and launching in China in the future, they hope to license it to Innovent and generate revenue through a profit-sharing mechanism.
In addition, General Manager Chien Tu-hsien told CNA reporters that TaiRx plans to apply for listing this year. In the second half of the year, they will first raise funds to increase their net worth, aiming to raise at least NT$400 million to NT$500 million to support subsequent R&D and international collaborations.
TaiRx held a media exchange event today. Lin Chun said that the Sintilimab immunotherapy has already been launched in China, used in combination with chemotherapy for non-small cell lung cancer and in combination with anti-angiogenesis drugs for liver cancer. This time, Innovent is providing the Sintilimab antibody drug for TaiRx's use to conduct a drug combination treatment for liver cancer.
He pointed out that by Innovent providing the antibody drug, TaiRx can save 90% of its clinical trial budget. If successfully launched in the future, it can also expand the indications for Sintilimab, achieving a win-win situation.
He said that regarding another important indication for CVM-1118, neuroendocrine tumors (NET), TaiRx is simultaneously advancing its international layout. Currently, they have completed a consultation meeting with the US Food and Drug Administration (FDA) and reached a clear consensus on the design of the next Phase 2B clinical trial, laying the foundation for subsequent development.
He added that to seek international cooperation opportunities, they have initiated contact with several European pharmaceutical companies and entered the due diligence and negotiation stages. They hope to accelerate the product's development process in the global market through licensing or strategic partnerships. (Editor: Chang Liang-chih) 1150423
(CNA Reporter He Hsiu-ling, Taipei, 23rd) Lin Chun, Chairman of the novel drug company TaiRx, stated that their investigational anti-cancer drug CVM-1118 will be combined with the Chinese pharmaceutical company Innovent's antibody drug 'Sintilimab' to conduct a Phase 2A combination clinical trial for the treatment of liver cancer, and they will begin recruiting patients. Upon receiving regulatory approval and launching in China in the future, they hope to license it to Innovent and generate revenue through a profit-sharing mechanism.
In addition, General Manager Chien Tu-hsien told CNA reporters that TaiRx plans to apply for listing this year. In the second half of the year, they will first raise funds to increase their net worth, aiming to raise at least NT$400 million to NT$500 million to support subsequent R&D and international collaborations.
TaiRx held a media exchange event today. Lin Chun said that the Sintilimab immunotherapy has already been launched in China, used in combination with chemotherapy for non-small cell lung cancer and in combination with anti-angiogenesis drugs for liver cancer. This time, Innovent is providing the Sintilimab antibody drug for TaiRx's use to conduct a drug combination treatment for liver cancer.
He pointed out that by Innovent providing the antibody drug, TaiRx can save 90% of its clinical trial budget. If successfully launched in the future, it can also expand the indications for Sintilimab, achieving a win-win situation.
He said that regarding another important indication for CVM-1118, neuroendocrine tumors (NET), TaiRx is simultaneously advancing its international layout. Currently, they have completed a consultation meeting with the US Food and Drug Administration (FDA) and reached a clear consensus on the design of the next Phase 2B clinical trial, laying the foundation for subsequent development.
He added that to seek international cooperation opportunities, they have initiated contact with several European pharmaceutical companies and entered the due diligence and negotiation stages. They hope to accelerate the product's development process in the global market through licensing or strategic partnerships. (Editor: Chang Liang-chih) 1150423